- Conditions
- Binge-Eating Disorder, Obesity
- Interventions
- NB medication (Naltrexone Bupropion combination), Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–36
of 36
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Obesity, Cardiovascular Diseases
- Interventions
- Naltrexone HCl/Bupropion HCl ER, Placebo
- Drug
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 139
- States / cities
- Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
- Conditions
- Obesity, Overweight
- Interventions
- Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,742 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
- Conditions
- Obesity
- Interventions
- Not listed
- Lead sponsor
- Currax Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31,889 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Brentwood, Tennessee
- Conditions
- Obesity
- Interventions
- Naltrexone-Bupropion Combination
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Binge-Eating Disorder
- Interventions
- Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Schizophrenia, Diabetes Mellitus, Type 2, Obesity
- Interventions
- Naltrexone, Bupropion, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Methamphetamine Use Disorder
- Interventions
- Naltrexone: Vivitrol®, Placebo (PLB) Injectable, Bupropion: Wellbutrin XL®, Placebo (PLB) Oral
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Francisco, California • Minneapolis, Minnesota + 5 more
- Conditions
- Obesity
- Interventions
- Naltrexone-Bupropion (NB) Combination, Placebo
- Drug
- Lead sponsor
- Currax Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 140
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 111 more
- Conditions
- Obesity
- Interventions
- Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 35 Years to 60 Years
- Enrollment
- 30 participants
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana
- Conditions
- Binge-Eating Disorder, Obesity
- Interventions
- Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment)
- Behavioral · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut